TempraMed Launches New Product, VIVI Cap Smart, Expanding Its Portfolio to Include a Digital Health Offering
Highlights: Expands TempraMed's product portfolio and adds a digital component to track and record medication use. First in the world platform that turns almost every insulin and GLP-1 pens to be connected and with a temperature shield. Unlocks significant pharma, healthcare provider, and real-time data opportunity to track compliance, efficacy, side effects, and other important information. Adds subscription-based business model to produ
Technology, Biotechnology, Pharmaceuticals, Health
2025-12-26 5:00 PM EST | TempraMed Technologies Ltd
Obesity Medicine Association Releases Position Statement: A New Era for Medicare & Medicaid Obesity Medication Coverage
Centennial, Colorado--(Newsfile Corp. - December 24, 2025) - The Obesity Medicine Association (OMA) released its Position Statement on Medicare and Medicaid Coverage and Expanded Access to Obesity Medications, detailing the association's recommendations and support for emerging federal policies expected to dramatically improve treatment access for millions of Americans living with obesity. The OMA commends the Centers for Medicare
Healthcare and Hospitals, Health
2025-12-24 8:00 AM EST | Obesity Medicine Association
A Year of Purpose and Progress: Dr. Christina Rahm Celebrates Global Growth, Scientific Breakthroughs, and International Honors
Franklin, Tennessee--(Newsfile Corp. - December 23, 2025) - From global stages and scientific breakthroughs to philanthropic leadership and international recognition, 2025 has marked a defining year for Dr. Christina Rahm. As Chief Science Officer of The ROOT Brands and founder of DRC Ventures, Dr. Rahm continues to lead at the intersection of science, sustainability and purpose-driven innovation. Her work this year has expanded far beyond the laboratory, spanning continents, empowering commu
Biotechnology, Food / Beverages, Health
2025-12-23 11:41 AM EST | DRC Ventures
Hemostemix Appoints Dr. David B. Alper, to Lead Multidisciplinary Physician Education in the Use of ACP-01
Calgary, Alberta--(Newsfile Corp. - December 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), an autologous stem cell company treating those who suffer in pain from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, dilated cardiomyopathy, total body ischemia, vascular dementia, is pleased to announce the appointment of Dr. David B. Alper, DPM, FFPM RCPS, to a lead role as Multidisciplinary Physic
Biotechnology, Pharmaceuticals, Health
2025-12-23 9:10 AM EST | Hemostemix Inc.
Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762
King of Prussia, Pennsylvania--(Newsfile Corp. - December 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that it has taken a
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-12-23 8:45 AM EST | Phio Pharmaceuticals Corp.
LIS Technologies Inc. Announces Critical Regulatory Milestone with Receipt of a State of Tennessee Radioactive Material License for Its State-of-the-Art Test Demonstration Facility Located at the K-1330 Building on the Historic K-25 Site
Oak Ridge, Tennessee--(Newsfile Corp. - December 23, 2025) - LIS Technologies Inc. ("LIST" or "the Company"), a proprietary developer of advanced laser technology and the only USA-origin and patented laser uranium enrichment company, today announced that it has received a Radioactive Material License from the State of Tennessee for its state-of-the-art Test Demonstration Facility located in the K-1330 building on the historic K-25 site in Oak Ridge, Tennessee.
Technology, Mining and Metals, Energy, Health
2025-12-23 8:10 AM EST | LIS Technologies Inc.
Restart Life Receives Aggregate Gross Proceeds of Approximately $590,000 from Warrant Exercises and Loan
Vancouver, British Columbia--(Newsfile Corp. - December 22, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that it has received aggregate gross proceeds of approximately CAD$590,000 through the exercise of previously issued common share purchase warrants and the closing of a corporate loan. The Company reports that holders of previously issued warrants exercised an aggregate of 4,103,023 warrants for
Technology, Biotechnology, Health
2025-12-22 12:00 PM EST | Restart Life Sciences Corp.
Functional Brands Inc. Launches Kirkman's(R) Skin, Beauty & Anti-Aging Bundle: A Science-Backed Approach to Radiant, Resilient Skin
Lake Oswego, Oregon--(Newsfile Corp. - December 22, 2025) - Functional Brands Inc. (NASDAQ: MEHA), a leading innovator in wellness and performance products, today announced the release of its Skin, Beauty & Anti-Aging Bundle by Kirkman®; a holistic solution designed to promote healthy, youthful skin by supporting detoxification, cellular renewal, and protection against environmental stressors. This carefully crafted bundle combines four powerful ingredients—Reduced Glutathione,
Household / Consumer / Cosmetics, Health
2025-12-22 8:00 AM EST | Functional Brands Inc.
Restart Life Sciences Signs Binding LOI to Acquire The Holy Crap Foods Portfolio of Brands and Manufacturing Plant
Vancouver, British Columbia--(Newsfile Corp. - December 22, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart" or the "Company") is pleased to announce that it has signed a binding letter of intent dated December 21st, 2025 (the "LOI"), which sets out the proposed terms by which the Company would acquire 100% of the shares of Holy Crap Foods Inc. ("Holy Crap"), from Happy Belly Food Group Inc. (CSE: HBFG) (the "Ac
Technology, Biotechnology, Health
2025-12-22 8:00 AM EST | Restart Life Sciences Corp.
CBIH Welcomes Federal Momentum Toward Cannabis Rescheduling as 2026 Opens a New Window to Accelerate Medical Innovation and Growth, with CBIH Positioned to Capitalize on Emerging Opportunities
Houston, Texas--(Newsfile Corp. - December 22, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) (CBIH) announces a landmark corporate and industry moment following recent indications that President Donald Trump will support federal actions that advance the rescheduling of marijuana from Schedule I to Schedule III. The development is widely regarded as one of the most consequential policy shifts in nearly two decades of national debate. After eighte
Biotechnology, Pharmaceuticals, Cannabis, Health
2025-12-22 7:00 AM EST | Cannabis Bioscience International Holdings
New Obesity Medicine Association Initiative Aims to Scale High-Impact Obesity Healthcare Improvements Nationwide
Centennial, Colorado--(Newsfile Corp. - December 18, 2025) - The Obesity Medicine Association (OMA) is pleased to announce a new multi-phase Quality Improvement (QI) initiative designed to strengthen obesity care delivery across diverse outpatient clinical settings in the United States. This initiative offers OMA members a unique opportunity to enhance systems of care, streamline workflows, and implement proven, evidence-based interventions for patients with obesity. This program is a c
Healthcare and Hospitals, Health
2025-12-18 2:00 PM EST | Obesity Medicine Association
Tersis Technologies Announces Strategic Initiatives Designed to Address Global Environmental and Economic Pressures
Brooksville, Florida--(Newsfile Corp. - December 18, 2025) - Tersis Technologies (OTCID: TERS) ("Tersis"), now trading under the ticker TERS, today announced strategic initiatives that place the company at the center of global environmental and economic transformation. The company is advancing integrated systems that support clean energy creation, carbon recovery, soil regeneration, water security, and circular economic development. At a time of accelerating global instability, communit
Agriculture, Energy, Alternative Energy, Health
2025-12-18 9:30 AM EST | Tersis Technologies Inc.
Edison Issues Report on MindMaze Therapeutics (MMTX)
London, United Kingdom--(Newsfile Corp. - December 18, 2025) - Edison issues report on MindMaze Therapeutics (SIX: MMTX). MindMaze Therapeutics is a commercial-stage health technology company pioneering AI-driven digital neurotherapeutic solutions for treatment and recovery after neurological events such as stroke and traumatic brain injury (TBI). Its unique, integrated and coordinated platform spans the full continuum of care. With the US FDA and CE/MDR registrations and a unique US CP
Banking / Financial Services, Computer Hardware, Computer Software, Health
2025-12-18 9:12 AM EST | Edison Group
Restart Life Closes Over-Subscribed Second Tranche Financing
Vancouver, British Columbia--(Newsfile Corp. - December 18, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") announces that further to its news release dated November 12, 2025 and December 5, 2025, the Company has closed the over-subscribed second tranche of its non-brokered private placement for total gross proceeds of CDN$630,000 (the "Placement"). As announced on November 12, 2025, the company intended to raise a total of up t
Technology, Biotechnology, Health
2025-12-18 8:00 AM EST | Restart Life Sciences Corp.
Akanda Corp. Welcomes Momentum Towards Cannabis Reform in the United States
Toronto, Ontario--(Newsfile Corp. - December 18, 2025) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company") applauds the recent reports that US President Donald Trump and his administration are considering changes and the reclassification of federal cannabis policy in the USA, including potential rescheduling of cannabis from Schedule I to Schedule III. Schedule III drugs are considered to have a medical value and a lower abuse potential as defined by the Drug Enforcement Administra
Cannabis, Health, Cannabis Cultivator, Cannabis Manufacturer
2025-12-18 7:30 AM EST | Akanda Corp
BioHarvest Sciences Awarded $1.6 Million USD Grant from the Israeli Innovation Authority to Advance Second-Generation Botanical Synthesis Platform
British Columbia and Rehovot, Israel--(Newsfile Corp. - December 18, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a biotechnology company pioneering its proprietary Botanical Synthesis™ platform, today announced that it has been awarded a $1.6 million grant from the Israeli Innovation Authority (IIA). The grant was approved under the IIA's Bio-Convergence
Biotechnology, Pharmaceuticals, Health
2025-12-18 7:30 AM EST | BioHarvest Sciences Inc.
Optimi Health Announces Appointment of New Director
Vancouver, British Columbia--(Newsfile Corp. - December 18, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian GMP-compliant manufacturer of MDMA and psilocybin, is pleased to announce the appointment of Mr. Jason Mosberian as a director of the Company, effective immediately (the "Appointment"). Mr. Mosberian graduated from the Sauder School of Business and earned his CPA designation in 2011 working in audit in
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-12-18 7:00 AM EST | Optimi Health Corp.
Therma Bright Inc. Investee Company, InStatin Expands its Inhaled Statin Programs to include COPD (Chronic Obstructive Pulmonary Disease) as its Lead Indication.
Toronto, Ontario--(Newsfile Corp. - December 18, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to provide an update on Investee company, InStatin. InStatin, a biotechnology company developing inhaled statin therapies for respiratory diseases, today reported significant progress from June 2024 through December 2025, despite a
Technology, Biotechnology, Health
2025-12-18 7:00 AM EST | Therma Bright Inc.
DiagnosTear Signs Non-Binding Term Sheet with Sheba Impact and Ramot to Exclusively License New Eye Imaging Technology, CLARIFY, Enabling Needle-Free Blood Count
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a leader in rapid eye based diagnostic technologies, is pleased to announce that the Company has signed a non-binding term sheet with Sheba Impact, the Technology Transfer office ("TTO") of Sheba Medical Center ("Sheba MC"), Israel's largest hospital and one of the world's most innovative clinical research institu
2025-12-17 6:00 PM EST | DiagnosTear Technologies Inc.
TempraMed Expands U.S. Manufacturing Capacity with New Production Facility in Florida
Highlights: Manufacturing site in Florida expands TempraMed's U.S. production footprint Increases capacity to meet rising demand from healthcare organizations, pharmacies, payors, and device manufacturers Shortens delivery timelines and improves service for customers in the United States where majority of devices have been sold to date Reduces COGS through localized production, improved logistics
Technology, Biotechnology, Pharmaceuticals, Health
2025-12-17 5:00 PM EST | TempraMed Technologies Ltd